OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
Kyoung Hwa Ha, Bongseong Kim, Hae Sol Shin, et al.
Korean Circulation Journal (2018) Vol. 48, Iss. 5, pp. 395-395
Open Access | Times Cited: 13
Kyoung Hwa Ha, Bongseong Kim, Hae Sol Shin, et al.
Korean Circulation Journal (2018) Vol. 48, Iss. 5, pp. 395-395
Open Access | Times Cited: 13
Showing 13 citing articles:
Cardiovascular Research Using the Korean National Health Information Database
Eue‐Keun Choi
Korean Circulation Journal (2020) Vol. 50, Iss. 9, pp. 754-754
Open Access | Times Cited: 204
Eue‐Keun Choi
Korean Circulation Journal (2020) Vol. 50, Iss. 9, pp. 754-754
Open Access | Times Cited: 204
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
Pin‐Nan Cheng, Wen‐Jone Chen, Charles Jia‐Yin Hou, et al.
Clinical and Molecular Hepatology (2023) Vol. 30, Iss. 1, pp. 16-36
Open Access | Times Cited: 10
Pin‐Nan Cheng, Wen‐Jone Chen, Charles Jia‐Yin Hou, et al.
Clinical and Molecular Hepatology (2023) Vol. 30, Iss. 1, pp. 16-36
Open Access | Times Cited: 10
The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure
Benjamin M. Scirica
JAMA Cardiology (2016) Vol. 1, Iss. 2, pp. 123-123
Open Access | Times Cited: 24
Benjamin M. Scirica
JAMA Cardiology (2016) Vol. 1, Iss. 2, pp. 123-123
Open Access | Times Cited: 24
Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis
Yuichi Chikata, Hiroshi Iwata, Katsutoshi Miyosawa, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 9
Yuichi Chikata, Hiroshi Iwata, Katsutoshi Miyosawa, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 9
Cardiovascular risks associated with dipeptidyl peptidase‐4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study
Maki Komamine, Kazuhiro Kajiyama, Chieko Ishiguro, et al.
Pharmacoepidemiology and Drug Safety (2019) Vol. 28, Iss. 9, pp. 1166-1174
Closed Access | Times Cited: 11
Maki Komamine, Kazuhiro Kajiyama, Chieko Ishiguro, et al.
Pharmacoepidemiology and Drug Safety (2019) Vol. 28, Iss. 9, pp. 1166-1174
Closed Access | Times Cited: 11
Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus
Yanyu Lin, Shuen-Fu Weng, Chung-Huei Hsu, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 7
Yanyu Lin, Shuen-Fu Weng, Chung-Huei Hsu, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 7
Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea
Da Hea Seo, Kyoung Hwa Ha, So Hun Kim, et al.
Endocrinology and Metabolism (2021) Vol. 36, Iss. 1, pp. 70-80
Open Access | Times Cited: 6
Da Hea Seo, Kyoung Hwa Ha, So Hun Kim, et al.
Endocrinology and Metabolism (2021) Vol. 36, Iss. 1, pp. 70-80
Open Access | Times Cited: 6
Dapagliflozin-Saxagliptin Combination - The Quest for Optimal Glycemic Control With Cardio-Renal Protection in Type 2 Diabetes Mellitus: An Expert Consensus in Indian Settings
Sujoy Ghosh, SUBHASH KUMAR WANGNOO, Sachin Chittawar, et al.
Journal of Endocrinology and Metabolism (2024) Vol. 14, Iss. 3, pp. 128-148
Open Access
Sujoy Ghosh, SUBHASH KUMAR WANGNOO, Sachin Chittawar, et al.
Journal of Endocrinology and Metabolism (2024) Vol. 14, Iss. 3, pp. 128-148
Open Access
Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study
Seung Min Chung, Jun Sung Moon, Jun Hwa Hong, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2181-2190
Closed Access
Seung Min Chung, Jun Sung Moon, Jun Hwa Hong, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2181-2190
Closed Access
Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
Kwang‐Il Kim
Korean Circulation Journal (2018) Vol. 48, Iss. 5, pp. 430-430
Open Access
Kwang‐Il Kim
Korean Circulation Journal (2018) Vol. 48, Iss. 5, pp. 430-430
Open Access
A prospective cohort study on effects of gemigliptin on cardiovascular outcomes in patients with type 2 diabetes (OPTIMUS study)
Eun Heui Kim, Sang Soo Kim, Dong Jun Kim, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access
Eun Heui Kim, Sang Soo Kim, Dong Jun Kim, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access
Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors
Atsushi Tanaka, Koichi Node
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access
Atsushi Tanaka, Koichi Node
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access
Dipeptidyl Peptidase-4 Inhibitors Reduced Long-term Cardiovascular Risk in Japanese Diabetic Patients After Percutaneous Coronary Intervention via Insulin-like Growth Factor-1 Axis: A 10-year Follow-up Study
Yuichi Chikata, Hiroshi Iwata, Katsutoshi Miyosawa, et al.
Research Square (Research Square) (2021)
Open Access
Yuichi Chikata, Hiroshi Iwata, Katsutoshi Miyosawa, et al.
Research Square (Research Square) (2021)
Open Access
